Skip to content
Biotechnology News, Trends & Expert Insights

News

Global Human Liver Model Market Report 2026: Size, Share, Trends, and Forecast to 2030 | 3D Models and Organ-on-a-Chip Propel 15.03% CAGR and US$3.81 Billion Opportunity

BBiotechNews.io8 min read

3D liver models, organ-on-a-chip and AI enable earlier toxicity screening, reduce late-stage drug failures and animal testing, and accelerate safer, cost-efficient drug development.

Dublin, Nov. 16, 2026 (GLOBE NEWSWIRE) -- "Human Liver Model Market: 2026 Edition" has been added to ResearchAndMarkets.com's offering.

The global human liver model market was valued at US$1.64 billion in 2024 and is projected to reach US$3.81 billion by 2030, expanding at a CAGR of 15.03% during 2025-2030, according to the report. Growth is being supported by the rising prevalence of liver diseases, continued advances in 3D bioprinting and organ-on-a-chip platforms, increased investment in pharmaceutical research, and demand for more predictive alternatives to animal testing.

Non-alcoholic fatty liver disease (NAFLD/MASLD), alcoholic liver disease (ALD), viral hepatitis, and liver cancer are creating an urgent need for reliable research platforms that support drug discovery, disease modeling, toxicity assessment, and personalized medicine. Pharmaceutical and biotechnology companies are increasingly adopting human-derived liver models to improve preclinical decision-making, identify unsuitable drug candidates earlier, and reduce costly late-stage clinical failures.

Product Type Analysis

The human liver model market is segmented into 2D human liver models and 3D human liver models. The 2D segment includes cell lines and primary human hepatocytes, while the 3D segment comprises liver-on-a-chip systems, organoids, spheroids, and 3D bio printed tissues.

2D human liver models held the largest market share in 2024, supported by their cost-effectiveness, established protocols, and suitability for high-throughput screening and initial toxicity assessments. However, 3D human liver models are expected to record the fastest growth through 2030. Their ability to reproduce liver architecture, cell-cell interactions, and metabolic functions more accurately is increasing their value in drug discovery, disease modeling, and toxicology testing. Greater scalability and accessibility of 3D bioprinting and organ-on-a-chip technologies are also encouraging adoption across pharmaceutical and biotechnology research.

Application Analysis

By application, the market includes ADME studies, toxicology testing, disease modeling, and other uses. ADME studies accounted for the largest share in 2024 because they remain a critical component of early drug development. Human liver models enable companies to assess drug behavior under more relevant physiological conditions, helping eliminate unsuitable candidates before they enter resource-intensive development stages.

Toxicology testing is projected to be the fastest-growing application during the forecast period. Rising concern over drug-induced liver injury (DILI), stricter regulatory expectations, and the limitations of animal-based testing are increasing demand for advanced in vitro liver platforms. More predictive toxicity screening can strengthen drug safety evaluations while accelerating development timelines.

End-use and Regional Outlook

Pharmaceutical & biotechnology companies represented the leading end-use segment in 2024. These organizations use human liver models to assess drug metabolism, drug-drug interactions, and hepatotoxicity throughout preclinical development. Contract research organizations are expected to post the fastest growth as drug developers increasingly outsource specialized research to access advanced technologies, reduce infrastructure costs, and improve operational efficiency. Academic and research institutes also continue to contribute to innovation in liver disease research and tissue engineering.

North America held the largest regional share in 2024, reflecting substantial pharmaceutical and biotechnology R&D spending, advanced healthcare infrastructure, and regulatory support for innovative preclinical testing methods. Asia Pacific is forecast to grow at the fastest rate, driven by expanding biotechnology activity, increased medical research investment, improving healthcare systems, and a rising burden of liver disease.

Market Drivers, Challenges, and Trends

Key growth drivers include increasing liver disease prevalence, demand for alternatives to animal testing, greater investment in liver research, the expansion of personalized medicine, and the need for earlier identification of drug toxicity. Advanced human liver models can provide more relevant data for therapeutic development while supporting safer and more efficient research workflows.

High costs and technical complexity remain significant barriers, particularly for sophisticated 3D platforms. Specialized equipment, trained personnel, and substantial investment can restrict adoption among smaller companies and research institutions. Standardization, scalability, and reproducibility will remain important priorities as the market matures.

Major human liver model market trends include the integration of AI and machine learning, progress in tissue engineering, the transition from 2D systems to 3D and ex vivo models, and the emergence of hybrid and in silico approaches. Continued development of organ printing and microphysiological systems is expected to improve model accuracy, throughput, and commercial accessibility.

Competitive Landscape

The market remains moderately fragmented, with biotechnology startups, academic research groups, and established life sciences companies contributing to innovation. At the same time, consolidation is increasing in advanced 3D segments as companies pursue mergers and acquisitions, partnerships, and technology integration. Leading participants identified in the report include:

  • Organovo Holdings
  • InSphero
  • BioIVT LLC
  • Emulate Inc.
  • MatTek
  • Mimetas
  • CN Bio Innovations Ltd.
  • Cyfuse Biomedical KK
  • Corning Incorporated
  • Pheonix Bio
  • Stemcell Technologies
  • Pandorum Technologies
  • Kirkstall Ltd

Market participants are investing in product development, strategic partnerships, and expansion into emerging markets to strengthen their competitive positions. In February 2025, CN Bio launched the PhysioMimix DILI assay kit: Human 24. The all-in-one kit provides access to the company's FDA-recognized human Drug-Induced Liver Injury assay and enables users to assess up to eight conditions simultaneously through its liver microphysiological system.

Key Topics Covered:

1. Executive Summary

2. Introduction
2.1 Human Liver Model: An Overview
2.1.1 Introduction to Human Liver Model
2.1.2 Benefits of Human Liver Model
2.2 Human Liver Model Segmentation: An Overview
2.2.1 Human Liver Model Segmentation

3. Global Market Analysis
3.1 Global Human Liver Model Market: An Analysis
3.1.1 Global Human Liver Model Market: An Overview
3.1.2 Global Human Liver Model Market by Value
3.1.3 Global Human Liver Model Market by Product Type (2D Human Liver Model and 3D Human Liver Model)
3.1.4 Global Human Liver Model Market by Application (ADME Studies, Toxicology Testing, Disease Modeling and Others)
3.1.5 Global Human Liver Model Market by End-use (Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic and Research Institutes)
3.1.6 Global Human Liver Model Market by Region (North America, Europe, Asia Pacific and Rest of the World)
3.2 Global Human Liver Model Market: Product Type Analysis
3.2.1 Global Human Liver Model Market by Product Type: An Overview
3.2.2 Global 2D Human Liver Model Market by Value
3.2.3 Global 2D Human Liver Model Market by Product Type (Cell Lines and Primary Human Hepatocytes)
3.2.4 Global Cell Lines 2D Human Liver Model Market by Value
3.2.5 Global Primary Human Hepatocytes 2D Human Liver Model Market by Value
3.2.6 Global 3D Human Liver Model Market by Value
3.2.7 Global 3D Human Liver Model Market by Product Type (Liver-on-a-chip, Organoids, Spheroids and 3D bio printed tissues)
3.2.8 Global Liver-on-a-chip 3D Human Liver Model Market by Value
3.2.9 Global Organoids 3D Human Liver Model Market by Value
3.2.10 Global Spheroids 3D Human Liver Model Market by Value
3.2.11 Global 3D Bio printed Tissues Human Liver Model Market by Value
3.3 Global Human Liver Model Market: Application Analysis
3.3.1 Global Human Liver Model Market by Application: An Overview
3.3.2 Global ADME Studies Human Liver Model Market by Value
3.3.3 Global Toxicology Testing Human Liver Model Market by Value
3.3.4 Global Disease Modeling Human Liver Model Market by Value
3.3.5 Global Others Human Liver Model Market by Value
3.4 Global Human Liver Model Market: End-use Analysis
3.4.1 Global Human Liver Model Market by End-use: An Overview
3.4.2 Global Pharmaceutical & Biotechnology Companies Human Liver Model Market by Value
3.4.3 Global Contract Research Organizations Human Liver Model Market by Value
3.4.4 Global Academic and Research Institutes Human Liver Model Market by Value

4. Regional Market Analysis
4.1 North America Human Liver Model Market: An Analysis
4.1.1 North America Human Liver Model Market: An Overview
4.1.2 North America Human Liver Model Market by Value
4.1.3 North America Human Liver Model Market by Region (The US, Canada and Mexico)
4.1.4 The US Human Liver Model Market by Value
4.1.5 Canada Human Liver Model Market by Value
4.1.6 Mexico Human Liver Model Market by Value
4.2 Europe Human Liver Model Market: An Analysis
4.2.1 Europe Human Liver Model Market: An Overview
4.2.2 Europe Human Liver Model Market by Value
4.2.3 Europe Human Liver Model Market by Region (Germany, UK, France, Italy, Spain and Rest of Europe)
4.2.4 Germany Human Liver Model Market by Value
4.2.5 United Kingdom Human Liver Model Market by Value
4.2.6 France Human Liver Model Market by Value
4.2.7 Italy Human Liver Model Market by Value
4.2.8 Spain Human Liver Model Market by Value
4.2.9 Rest of Europe Human Liver Model Market by Value
4.3 Asia Pacific Human Liver Model Market: An Analysis
4.3.1 Asia Pacific Human Liver Model Market: An Overview
4.3.2 Asia Pacific Human Liver Model Market by Value
4.3.3 Asia Pacific Human Liver Model Market by Region (China, Japan, India, South Korea and Rest of Asia Pacific)
4.3.4 China Human Liver Model Market by Value
4.3.5 Japan Human Liver Model Market by Value
4.3.6 India Human Liver Model Market by Value
4.3.7 South Korea Human Liver Model Market by Value
4.3.8 Rest of Asia Pacific Human Liver Model Market by Value
4.4 Rest of the World Human Liver Model Market: An Analysis
4.4.1 Rest of the World Human Liver Model Market: An Overview
4.4.2 Rest of the World Human Liver Model Market by Value

5. Market Dynamics
5.1 Growth Drivers
5.1.1 Increasing Prevalence of Liver Diseases
5.1.2 Growing Demand for Alternatives to Animal Testing
5.1.3 Increasing Focus on Personalized Medicine
5.1.4 Growing Investment in Liver Research
5.1.5 The Growing Need for Early Drug Toxicity Diagnosis
5.2 Challenges
5.2.1 High Cost of Liver Models
5.2.2 Dearth of Skilled Professionals
5.3 Market Trends
5.3.1 Integration of AI and Machine Learning
5.3.2 Advancements in Organ Printing and Tissue Engineering Technologies
5.3.3 Shift from 2D to Advanced 3D and Ex Vivo Models
5.3.4 Rise of Hybrid and In Silico Models

6. Competitive Landscape
6.1 Global Human Liver Model Market Players: Competitive Landscape
6.1.1 Global Human Liver Model Market Players: An Overview
6.2 Global Human Liver Model Market Players: Recent Developments

7. Company Profiles
7.1 Corning Incorporated
7.1.1 Business Overview
7.1.2 Operating Segments
7.1.3 Business Strategies
7.2 Organovo Holdings Inc.
7.2.1 Business Overview
7.2.2 Business Strategies
7.3 InSphero AG
7.3.1 Business Overview
7.3.2 Business Strategies
7.4 BioIVT LLC
7.4.1 Business Overview
7.4.2 Business Strategies
7.5 Emulate Inc.
7.5.1 Business Overview
7.5.2 Business Strategies
7.6 MatTek (The BICO Group)
7.6.1 Business Overview
7.6.2 Business Strategies
7.7 MIMETAS
7.7.1 Business Overview
7.7.2 Business Strategies
7.8 CN Bio Innovations Ltd.
7.8.1 Business Overview
7.8.2 Business Strategies
7.9 Cyfuse Biomedical K.K.
7.9.1 Business Overview
7.9.2 Business Strategies
7.10 PhoenixBio Co., Ltd.
7.10.1 Business Overview
7.10.2 Business Strategies
7.11 STEMCELL Technologies
7.11.1 Business Overview
7.11.2 Business Strategies
7.12 Pandorum Technologies Pvt. Ltd.
7.12.1 Business Overview
7.13 Kirkstall Ltd.
7.13.1 Business Overview

List of Figures [81]

Companies Featured

  • Corning Incorporated
  • Organovo Holdings Inc.
  • InSphero AG
  • BioIVT LLC
  • Emulate Inc.
  • MatTek (The BICO Group)
  • MIMETAS
  • CN Bio Innovations Ltd.
  • Cyfuse Biomedical K.K.
  • PhoenixBio Co., Ltd.
  • STEMCELL Technologies
  • Pandorum Technologies Pvt. Ltd.
  • Kirkstall Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/tjxhsq

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900